Novo Nordisk: latest news - GoINPHARMA
Tuesday, 11 December 2018 - 23:39

Novo Nordisk

Novo Nordisk announces new job cut plan affecting 1,300 employees

Denmark-based group Novo Nordisk has announced its third-quarter financial results, which were below expectations again. The group’s profits were DK9.04bn, that is 7.5% less than Q3 2017, while sales were 2% below last year’s figures. The Danish group’s management has…

Novo Nordisk announces new spate of job cuts

Denmark-based  Novo Nordisk will cut 250 jobs in the US. The news was announced on Friday evening after trading closed and will affect 100 employees at Princeton premises (NJ) and 150 employees working in the diabetes area with support tasks….

Novo Nordisk announces as many as 400 job cuts in research

Denmark-based Novo Nordisk, world leader in diabetes treatments, today has announced a plan to dismiss 400 research employees. Cuts will mainly affect employees in Denmark and China. The company will use the saved resources to increase its innovation capacity: indeed…

3,000 impending dismissals reported in Novo Nordisk

The Danish economic and financial daily Börsen has published a long article about Novo Nordisk and the rumors that started circulating yesterday, reporting that the company is planning cost cuts that would result in 3,000 dismissals and a downward revision…

Positive momentum for Novo thanks to GLP-1 therapies

The French economic and financial daily Les Echos has published an analysis of pharmaceutical group Novo Nordisk. Many analysts expected negative Q1 results from the company, since diabetes therapies account for 80% of its portfolio, and the diabetes business is…

Novo Nordisk’s Ozempic approved also in Europe

Denmark-based Novo Nordisk yesterday announced that the European Commission has approved Ozempic (semaglutide) for the treatment of type-2 diabetes as a once-weekly treatment in a Multi-Dose Pen. Novo Nordisk expects to launch Ozempic in Europe in H2 2018. Ozempic has…

Diabetes business increasingly struggling

In the past, the diabetes business used to deliver excellent margins and considerable growth rate, which encouraged many companies to join it and launch new products. Increased competition and pressure on prices by authorities have resulted in the current global-scale…

Novo Nordisk’s growth slows down

Novo Nordisk has announced today its 2017 financial results, which are not as positive as analysts expected, thus shares have declined by over 6% (Copenhagen). Sales were DKK112bn (€15bn) and reported operating profit was DKK49bn (+1%). The Diabetes care and…

Battle over Ablynx begins

Bloomberg has reported that Denmark-based Novo Nordisk is preparing a new bid to acquire Belgium-based biotech Ablynx. The offer would significantly improve the previous one-€2.6bn-and could be submitted as early as next week. Ablynx has tried to enter into talks…

Novo Nordisk offers €2.6bn for Belgium-based Ablynx

The Belgian biotech sector appears to be fairly attractive to the big pharma. After last Friday’s announcement that Takeda had acquired Belgium-based Tigenix for €520m, Denmark-based Novo Nordisk has announced today it has offered €2.6bn for Belgian biotech company Ablynx….

Positive momentum for Novo: Ozempic (semaglutide) approved

Novo Nordisk yesterday announced that FDA has approved Ozempic (semaglutide), GLP-1’s analog, and the Danish group’s shares have soon risen over 3% (Copenhagen). Ozempic is proposed as a once-weekly injection. The new product will be sold at $676 per prescription….

NovoNordisk’s CSO openly addresses state of pharma sector

Novo Nordisk’s CSO Mads Krogsgaard has addressed in a long interview the overall state of the pharma sector. The Danish manager has voiced his skepticism about the market’s increasing interest in the NASH (Non-Alcoholic Steatohepatitis) business, that he deems unjustified,…

Novo Nordisk targets a new treatment area through an acquisition

Danish economic-financial daily Borsen today has reported a statement by Novo Nordisk’s head of research Peter Kurthals, who has said that the group is planning to access a new treatment area through a large acquisition. Novo Nordisk is already focusing…

Novo Nordisk discloses ambitious development plans for obesity drugs

Denmark-based Novo Nordisk yesterday announced at a meeting with investors that it plans to conduct a Phase-III PIONEER clinical trial with as many as 4,500 patients with obesity, assessing the investigational drug semaglutide (NN9536). The decision reflects the highly positive…

Novo’s Tresiba approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for diabetes treatment. The product is a basal, new-generation insulin, to be taken once daily, that provides an ultra-long duration of action. Tresiba has…

Novo’s Victoza, new indication to reduce CV risk

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER…

The best drug is not always a guarantee for the best financial results

Novo Nordisk demonstrated to investors and analysts that the best and most advanced drug is not always the product which ensures the best financial results. The Denmark-based pharmaceutical giant recently launched on the market Tresiba, a novel, advanced insulin for…

Novo focuses on new obesity therapy Semaglutide

Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…

Novo’s Victoza, positive opinion by FDA EMDAC on cardiovascular outcomes

Novo Nordisk announced that FDA EMDAC (Endocrinologic and Metabolic Drugs Advisory Committee) discussed the sNDA (supplemental New Drug Application) submitted by the company in order to have data on cardiovascular outcomes from the LEADER trial included in Victoza’s label (liraglutide)….